Biomarkers /
PLCB4
Overview
PLCB4 is altered in 2.18% of all cancers with melanoma, cutaneous melanoma, conventional glioblastoma multiforme, skin squamous cell carcinoma, and adenocarcinoma of unknown primary having the greatest prevalence of alterations [3].
The most common alterations in PLCB4 are PLCB4 Mutation (2.14%), PLCB4 G876E (0.11%), PLCB4 E1072K (0.13%), PLCB4 S342L (0.08%), and PLCB4 W548* (0.08%) [3].
Clinical Trials
Significance of PLCB4 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.